Clinical Trials Directory

Trials / Conditions / Metastatic Castration-Resistant Prostate Carcinoma

Metastatic Castration-Resistant Prostate Carcinoma

11 registered clinical trials studyying Metastatic Castration-Resistant Prostate Carcinoma — 7 currently recruiting.

StatusTrialSponsorPhase
RecruitingNovel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
NCT06705686
TechnoGenesys, Inc.Phase 1
Not Yet RecruitingTesting Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients
NCT07200830
Alliance for Clinical Trials in OncologyPhase 3
RecruitingLow PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Res
NCT06526299
University of WashingtonPhase 2
RecruitingSPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
NCT07096999
University of Michigan Rogel Cancer Center—
Active Not RecruitingGolimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
NCT05960578
University of WashingtonPhase 2
RecruitingPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
NCT06099093
Brigham and Women's HospitalPhase 4
Active Not RecruitingTesting the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
NCT05828082
National Cancer Institute (NCI)Phase 2
RecruitingAbemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT05113537
Vadim S KoshkinPhase 1 / Phase 2
Active Not RecruitingAn Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
NCT04777071
University of WashingtonPhase 2
RecruitingRadiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication
NCT04071236
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedLean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity
NCT01621425
Radboud University Medical Center—